Inotersen

Overview

Inotersen (GSK-2998728; ISIS-420915) is a 2'-O-methoxyethyl-modified antisense oligonucleotide and transthyretin ( TTR ) inhibitor with low genotoxicity. Inotersen triggers RNase H1-mediated degradation by binding to TTR mRNA , thereby effectively reducing the production of both mutant and wild-type transthyretin in the liver. Inotersen significantly reduces amyloid fiber deposition, yet specific toxicities such as inflammation or tumors are observed at high doses in some animal models. Inotersen is used in studies of hereditary transthyretin amyloidosis and the associated polyneuropathy and cardiomyopathy.

Application

Products | Products > Disease Areas > Blood or Cardio-cerebrovascular Disease | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Disease Areas > Heart Disease | Products > Disease Areas > Cardiomyopathy | Products > Signaling Pathways > Neuronal Signaling | Products > Research Areas > Neurological Disease | Products > Research Areas > Cardiovascular Disease | Products > Signaling Pathways > Transthyretin (TTR)

Product Information

• Catalog No.: HY-112974
• CAS No.: 1492984-65-2
• Molecular Formula: C230H318N69O121P19S19
• Molecular Weight: 7183.08
• Purity: 96.44%
• Storage: -20°C, stored under nitrogen, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen, away from moisture)
• Availability: In-stock

Source

Original product source